Edition:
United Kingdom

OraSure Technologies Inc (OSUR.OQ)

OSUR.OQ on NASDAQ Stock Exchange Global Select Market

17.60USD
4:06pm GMT
Change (% chg)

$0.14 (+0.80%)
Prev Close
$17.46
Open
$17.35
Day's High
$17.66
Day's Low
$17.31
Volume
49,831
Avg. Vol
266,381
52-wk High
$23.00
52-wk Low
$8.40

Latest Key Developments (Source: Significant Developments)

OraSure Technologies reports Q3 earnings per share $0.09
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - OraSure Technologies Inc :OraSure Technologies Inc announces 2017 third quarter financial results.Q3 earnings per share $0.09.Q3 revenue $42.3 million versus I/B/E/S view $40.8 million.Q3 earnings per share view $0.09 -- Thomson Reuters I/B/E/S.Sees q4 2017 earnings per share $0.08 to $0.09.Sees q4 2017 revenue $45 million to $46 million.  Full Article

Orasure awarded up to $16.6 mln to advance rapid zika tests
Tuesday, 23 Aug 2016 

Orasure Technologies Inc : Awarded up to $16.6 million to advance rapid zika tests . Six-year, multi-phased contract includes an initial commitment of $7.0 million .Contract includes options for upto additional $9.6 million to fund evaluation of additional product enhancements,regulatory activities.  Full Article

Orasure Technologies reports earnings per share of $0.07
Wednesday, 3 Aug 2016 

Orasure Technologies Inc : Orasure announces 2016 second quarter financial results . Q2 earnings per share $0.07 . Q2 revenue $31.4 million versus I/B/E/S view $31.2 million . Q2 earnings per share view $0.05 -- Thomson Reuters I/B/E/S . Sees Q3 2016 earnings per share $0.07 to $0.08 . Orasure Technologies Inc sees consolidated net income for Q3 between $0.07 and $0.08 per share . Orasure Technologies Inc says company expects consolidated net revenues for Q3 to range from $31.25 million to $31.75 million .Q3 earnings per share view $0.08, revenue view $34.6 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Orasure Technologies' unit enters into $143 million deal for supply of Oragene Dx devices‍​

* Says unit has entered into a $143 million deal for the supply of Oragene Dx devices to a consumer genomics customer - SEC filing‍​ Source text for Eikon: Further company coverage: